PitchSend

Investor Presentation

GVB GVB TRANSACTION HIGHLIGHTS CANNABINOID LOTION 500 MILLIGRAMS (8 11 or (9) 200 WITTICKY ГОЦОИ CYTNYBIKOID GVB CANNABI CANNABINOID CREAM 500 MILLIG 122/CONL O GVB ego wirrie СЬЕVW СУИИВ BALM 1000 MILLIGRAMS (4120mL) 1000 WIFI ΒΗΓΙΝ СУИИУВIЙOID CAB GVB CANNABINOID GUMMIES 30 GUMMIES 25MG EACH (750mg) ball 32WC EVCH 30 COWWIE? enWWIE? СУИИУВIЙОID CVB CANNABINOID TINCTURE 500 MILLIGRAMS BAWYDOND DOO PIETIC SWI ПИСIПКЕ CVMMVBIMOID CAB Transaction Considerations Consideration to GVB Biopharma Employee Retention Board of Directors Financial Update ▪ 22nd Century acquires all of the issued and outstanding shares of GVB Biopharma ▪ Pro forma ownership of approximately 17% GVB Biopharma and 83% 22nd Century ■ Aggregate consideration of approximately $58 million, including: 1. the assumption of approximately $4.5 million of debt, 2. GVB's closing costs and 3. the issuance to GVB of an aggregate of 32,900,000 unregistered shares of common stock of 22nd Century. ▪ 22nd Century will enter into employment and consulting arrangements with certain key employees of GVB 22ND CENTURY GROUP GVB will nominate a director to 22nd Century's board of directors, provided that such nominee is independent and subject to approval by 22nd Century's Governance and Nominating Committee ▪ 22nd Century will furnish any pro forma financial information required no later than 71 calendar days after closing 26

View entire presentation